NAT-LANTHANUM TABLET (CHEWABLE)

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

LANTHANUM (LANTHANUM CARBONATE DIHYDRATE)

Disponible depuis:

NATCO PHARMA (CANADA) INC

Code ATC:

V03AE03

DCI (Dénomination commune internationale):

LANTHANUM CARBONATE

Dosage:

750MG

forme pharmaceutique:

TABLET (CHEWABLE)

Composition:

LANTHANUM (LANTHANUM CARBONATE DIHYDRATE) 750MG

Mode d'administration:

ORAL

Unités en paquet:

15G/50G

Type d'ordonnance:

Prescription

Domaine thérapeutique:

PHOSPHATE-REMOVING AGENTS

Descriptif du produit:

Active ingredient group (AIG) number: 0151709003; AHFS:

Statut de autorisation:

APPROVED

Date de l'autorisation:

2020-05-14

Résumé des caractéristiques du produit

_NAT-LANTHANUM Product Monograph _
_Page 1 of 33 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
NAT-LANTHANUM
Lanthanum carbonate dihydrate chewable tablets
Chewable tablets, 250 mg, 500 mg, 750 mg, and 1000 mg, oral
Phosphate binder
Natco Pharma (Canada) Inc.
Date of Initial Authorization:
2000 Argentia Road, Plaza 1, Suite 200
April 30, 2020
Mississauga, Ontario
L5N 1P7
Date of Revision:
August 24, 2023
Submission Control No: 275728
_ _
_NAT-LANTHANUM Product Monograph _
_Page 2 of 33 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Gastrointestinal
08/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL
CHANGES………………………………………………………………………………………….
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................................
4
4.1
Dosing Considerations
............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
....................................................... 4
4.4
Administration
........................................................................................................
5
4